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Abstract
Background and Aims: The PNPLA3 I148M sequence variant favors hepatic lipid accumulation and confers susceptibility to
hepatic fibrosis and hepatocellular carcinoma. The aim of this study was to estimate the effect size of homozygosity for the
PNPLA3 I148M variant (148M/M) on the fibrosis progression rate (FPR) and the interaction with age at infection in chronic
hepatitis C (CHC).
Methods: FPR was estimated in a prospective cohort of 247 CHC patients without alcohol intake and diabetes, with careful
estimation of age at infection and determination of fibrosis stage by Ishak score.
Results: Older age at infection was the strongest determinant of FPR (p,0.0001). PNPLA3 148M/M was associated with
faster FPR in individuals infected at older age (above the median, 21 years; 20.6460.2, n = 8 vs. 20.9560.3, n = 166 log10
FPR respectively; p = 0.001; confirmed for lower age thresholds, p,0.05), but not in those infected at younger age (p = ns).
The negative impact of PNPLA3 148M/M on fibrosis progression was more marked in subjects at risk of altered hepatic lipid
metabolism (those with grade 2–3 steatosis, genotype 3, and overweight; p,0.05). At multivariate analysis, PNPLA3 148M/M
was associated with FPR (incremental effect 0.0860.03 log10 fibrosis unit per year; p = 0.022), independently of several
confounders, and there was a significant interaction between 148M/M and older age at infection (p = 0.025). The association
between 148M/M and FPR remained significant even after adjustment for steatosis severity (p = 0.032).
Conclusions: We observed an interaction between homozygosity for the PNPLA3 I148M variant and age at infection in
determining fibrosis progression in CHC patients.
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Introduction
Hepatitis C virus (HCV) infection affects roughly 130–170
million people worldwide. Individuals with chronic HCV-related
hepatitis (CHC) are at high risk of liver fibrosis, an in about 20% of
cases CHC progresses to cirrhosis. Therefore, HCV is a leading
cause of end-stage liver disease and hepatocellular carcinoma [1].
Older age at infection, genotype 3, coexistent liver diseases, male
gender, alcohol abuse, obesity and diabetes, and steatosis are risk
factors for disease evolution [2–5].
However, even after taking into account all known viral, host
related, and environmental factors, the rate of progression to
advanced fibrosis is highly variable among individuals, thereby
suggesting a role for inherited variants. Indeed, single-nucleotide
polymorphisms at different genetic loci have been associated with
fibrosis progression in candidate gene studies [6,7].
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The rs738409 C.G polymorphism of Patatin-like phospholi-
pase domain-containing 3 (PNPLA3), encoding for the I148M
protein sequence variant, is the major common genetic determi-
nant of hepatic fat content. The I148M variant influences the
metabolism of triglycerides, lipid droplets remodeling, and
lipoprotein secretion in hepatocytes [8–13]. PNPLA3 I148M is
the major risk factor for both alcoholic and nonalcoholic
steatohepatitis, showing an age-modulated effect on liver damage
susceptibility and fibrogenesis [14–19]. Recently, it has been
reported that homozygosity for the 148M risk allele (henceforth
PNPLA3 148M/M) also influences the risk of advanced fibrosis
and hepatocellular carcinoma in CHC [20–25]. However, scant
data are derived from prospective studies [23,25], and the
interaction with age at infection has not been evaluated so far.
Therefore, the aim of this study was to estimate the effect size of
PNPLA3 148M/M on fibrosis progression rate (FPR) and the
interaction with age at infection in a unique validated cohort of
247 CHC subjects without significant alcohol intake and diabetes,
characterized by a careful estimation of age at infection and with
histological determination of liver damage [3].
Materials and Methods
Patients
We analyzed a previous published cohort of 247 CHC patients
followed-up at the Migliavacca Liver Disease Center at the
Fondazione IRCCS Ca’ Granda Policlinico of Milan [3]. Briefly,
inclusion criteria comprised a precise estimate of the date of
infection based on the date of the first reported risk factor, a
diagnostic liver biopsy before any antiviral therapy performed at
least 4 years after the date of infection, and no history of past or
current alcohol abuse. Patients with viral co-infections or other
liver diseases were excluded, as well as patients with either type 1
or type 2 diabetes. Disease duration was calculated considering the
time elapsed from the date of infection to the time of liver biopsy.
The study protocol conformed to the Declaration of Helsinki and
was approved by the Institutional Review Board of the
Fondazione IRCCS Ca’ Granda. Each patient signed a written
informed consent.
The baseline features of the study cohort stratified by PNPLA3
148M/M status are presented in table 1. The study database has
been uploaded as supplementary material (Data S1).
Histological evaluation
Liver histology was evaluated by a single expert pathologist.
Mean biopsy length was 26.3 mm. The severity of hepatic
inflammation was evaluated by the Ishak score [26], entailing a
maximum of 18 points for grading (G) and 6 points for liver
staging (S). All specimens were also evaluated for steatosis severity
(grade 0: absent or ,5%; grade 1: 5–33%; grade 2: 34–66%;
grade 3: .66% of hepatocytes affected) [27]. Steatosis assessment
is missing for 14 patients due to the inability to recollect the
original histological slides re-evaluated for fibrosis stage. To
analyze the effect of steatosis severity in the whole study cohort,
additional analyses were conducted estimating the severity of
steatosis in these 14 subjects by ultrasonography [28].
Genetic analysis
Genomic DNA was obtained from peripheral whole blood as
previously described [3]. The PNPLA3 rs738409 C.G single
nucleotide polymorphism, encoding for the I148M protein
sequence variant, was genotyped by a 59-nuclease Taqman assay
(LifeTechnologies, Carlsbad, CA, USA) at the Metabolic Liver
Diseases lab at the Fondazione Ca’ Granda IRCCS. Success rate
was 100% and perfect concordance between duplicates and
internal controls was observed.
Statistical analysis
For descriptive statistics, variables were shown as mean 6 SD
and frequencies, and compared by Student’s t-test or chi-square
test according to data distribution. P values were considered
significant when ,0.05 (two-tailed). FPR was calculated by taking
the ratio between the staging value of Ishak score and the disease
duration (years), and it was treated as a continuous variable. Mean
disease duration was 25610 years. Log10 transformation of FPR
was employed to obtain linearity. FPR estimation assumes that no
significant liver fibrosis was present at the time of infection, and
that liver fibrosis progression is constant during time [2]. A first
generalized linear model was formulated and fitted to the data,
specifying the presence of PNPLA3 148M/M at risk genotype
[21–23], and the covariates as explanatory variables. We
considered as covariated the independent predictors of FPR in a
previously reported analysis of the same cohort [3]: age at
infection (encoded as . or # the median value, 21 years), gender,
and HCV genotype. The product term age at infection x
PNPLA3 148M/M was fitted into the model to test the
interaction between PNPLA3 genotype and age at infection on
FPR. To account for other potential confounders, a second model
was tested, with further adjustement for the route of HCV
transmission (intra-venous drug use: IVDU or other), body-mass
(BMI , or $25 Kg/m2), and age at liver biopsy. Finally, to check
whether the relationship between PNPLA3 genotype and FPR
was independent of steatosis, a final model further adjusted for the
histological severity of steatosis (grade 2–3 vs. 0–1) was evaluated.
Models were checked through the regression diagnostic plots to
verify normality, linearity of the data, and constant variance. The
effect of the explanatory variables was considered significant if p,
0.05 (two-tailed). Analyses were performed by the SPSS 21.0
(IBM, Burbank, NY, USA) statistical analysis software.
Results
Study cohort
Detailed characterization of the study cohort has previously
been reported [3]. Briefly, 52% of patients were males, the
majority infected by genotype 1 (52%), during blood transfusion
(75%). Median age at infection was 21 years and disease duration
25 years. At the time of histological evaluation, 16% of patients
had cirrhosis, whereas severe steatosis (grade 2–3) was observed in
20% of cases. The frequency distribution of the PNPLA3 I148M
variant did not violate Hardy-Weinberg equilibrium (p.0.8), and
was in line with that expected unselected subjects: 120 patients
were PNPLA3 148I/I (48%), 106 148I/M (43%), and 21 had the
unfavorable 148M/M genotype (9%).
Clinical features of patients stratified by PNPLA3 148M/M
status are presented in table 1. Demographic and anthropometric
features, viral genotype distribution, age and route of infection,
and duration of follow-up did not differ according to PNPLA3
148M/M status (p = ns). There was no statistically significant
difference in the prevalence of grade 2–3 steatosis according to
PNPLA3 148M/M status (p = ns), although a nonsignificant trend
was observed in the whole cohort including subjects with
ultrasonographic estimation of steatosis severity (7/21, 33% vs.
44/226, 19% in 148M/M vs. individuals carrying other PNPLA3
genotypes, p= 0.15).
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Effect of age at infection and PNPLA3 148M/M on fibrosis
progression
Older age at infection was strongly associated with FPR (log10
FPR 21.160.3 vs.20.960.3 in subjects younger or older than 21
years, median value, respectively; p,0.0001). The FPR stratified
by age at infection (. or # median value, 21 years) and PNPLA3
148M/M and is presented in figure 1 and in table 2. PNPLA3
148M/M was associated with faster FPR in older (p = 0.001), but
not in younger patients (p = ns). The positive association between
PNPLA3 148M/M and FPR in older patients was confirmed in
sensitivity analyses using different age cut-offs (table 2): 15 years,
the 25th centile (p = 0.038), 18 years (p = 0.045), and 27 years, the
75th centile (p = 0.01).
Steatogenic factors, PNPLA3 148M/M, and fibrosis
progression
Moderate-severe steatosis was associated with faster FPR (log10
FPR 21.160.3 vs. 20.960.3 in subjects with steatosis grade 0–1,
n = 186 vs. grade 2–3, n= 47, respectively; p = 0.016). The
association between steatosis grade 2–3 and FPR was confirmed
in the whole cohort including subjects with ultrasonographic
estimation of steatosis severity (log10 FPR 21.160.3 vs. 20.960.3
in subjects with steatosis grade 0–1, n= 196 vs. grade 2–3, n= 51,
respectively; p = 0.012). Since PNPLA3 I148M interferes with
hepatocellular lipid metabolism, we next evaluated whether the
effect of PNPLA3 148M/M on FPR was influenced by steatosis
severity and risk factors for derangement of hepatic lipid
metabolism. Results are shown in table 3. The association of
PNPLA3 148M/M with FPR was more consistent in the presence
of grade 2–3 steatosis (p = 0.024), or in the presence of other
steatogenic factors: namely infection with genotype 3 (p = 0.005),
or overweight (p = 0.05). The association between PNPLA3
148M/M and FPR was nearly significant in patients with steatosis
grade 2–3 including subjects with ultrasonographic estimation of
steatosis severity (p = 0.056).
Independent predictors of fibrosis progression
At the multivariate generalized linear model considering known
determinants of FPR (age at infection, gender, and viral genotype:
shown in model 1, table 4) PNPLA3 148M/M was an indepen-
dent predictor of FPR (p= 0.022). The model estimated an
incremental progression of 0.0860.03 log10 unit of fibrosis per
year conferred by 148M/M status. Furthermore, there was a
significant interaction between PNPLA3 148M/M and older age
at infection in determining FPR (p= 0.025; estimate +0.0760.03).
In exploratory analyses, there was no significant interaction
between PNPLA3 148M/M and other determinants of FPR.
To test the robustness of the association between PNPLA3
genotype and FPR, we extended the model with further
adjustment for additional potential confounders: age at biopsy,
presence of overweight, and route of infection (model 2; table 4).
In this extended model, the association of PNPLA3 148M/M
with FPR (estimate +0.0860.03, p= 0.018), as well as the
interaction with older age at infection (estimate +0.0760.03,
p = 0.021) remained unaffected.
Finally, to test whether the effect of 148M/M status on fibrosis
progression was independent of the histological severity of
steatosis, we further adjusted the extended model for the presence
of grade 2–3 steatosis (model 3; table 4). Again, PNPLA3 148M/
M (estimate +0.0760.03, p= 0.032) and the interaction with older
age at infection (estimate +0.0760.03, p = 0.045) remained
significantly associated with FPR independently of the steatosis
severity (grade 2–3 vs. 0–1; estimate +0.0460.02, p = 0.03). In the
overall series of patients including those with ultrasonographic
Table 1. Clinical features of 247 CHC patients subdivided according to the presence of homozygosity for PNPLA3 I148M variant
(148M/M).
PNPLA3 I148M genotype p value
148I/I or I/M 148M/M
n=226 (91) n=21 (9)
Age at infection years 21.5613 21.7616 0.96
Sex F 109 (48) 9 (43) 0.66
BMI Kg/m2 26.1613 24.966 0.69
Age at biopsy years 46.8612 48.4613 0.70
HCV genotype 0.64
G1 116 (51) 13 (62)
G2 68 (30) 6 (28)
G3 32 (14) 2 (10)
G4 10 (5) 0
Route of infection 0.83
Transfusion 169 (75) 16 (76)
IVDU 53 (23) 5 (24)
Other 4 (2) 0
Steatosis grade 2–3 42 (19) 5 (26) 0.48
Disease activity (grade) 6 {5–7} 6 {5–7} 0.78
Fibrosis stage 2 {1–3} 3 {2–5} 0.22
Continous variables are shown as mean 6 SD (normally distributed) or median {interquartile range} (skewed variables); (): % values; F: female; BMI: body mass index; G:
genotype; IVDU: intra-venous drug user; Other: needlestick, mother-to-child, sexual transmission.
doi:10.1371/journal.pone.0106022.t001
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Figure 1. Fibrosis progression rate (FPR) according to age at infection (. or#21 years, median value) and PNPLA3 148M/M status in
247 patients with chronic hepatitis C. Box plots indicate median value and interquatile ranges, whiskers the 5th and 95th centiles. p = 0.001 for
faster FPR in PNPLA3 148M/M positive vs. negative patients with older age at infection (.21 years). *p,0.0001 vs. patients with same PNPLA3 148M/
M status and younger age at infection (#21 years).
doi:10.1371/journal.pone.0106022.g001
Table 2. Effect of PNPLA3 148M/M on (log10) FPR in 247 CHC patients according to different thresholds of age at infection.
PNPLA3 p value
148I/I or I/M 148M/M
15 years; 25th centile (6puberty)
Younger 21.2560.3 (51) 21.1960.3 (9) ns
Older 20.9860.3 (175) 20.7860.3 (12) 0.038
18 years; ‘‘adulthood’’
Younger 21.2560.3 (70) 21.1960.3 (9) ns
Older 20.9960.3 (156) 20.7860.3 (12) 0.045
21 years; median
Younger 21.1460.3 (110) 21.1660.3 (13) ns
Older 20.9560.3 (116) 20.6460.2 (8) 0.001
27 years; 75th centile
Younger 21.1060.3 (157) 21.1160.3 (14) ns
Older 20.9060.3 (69) 20.6760.2 (7) 0.01
(): number of subjects; ns: not significant.
doi:10.1371/journal.pone.0106022.t002
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estimation of steatosis, PNPLA3 148M/M (estimate +0.0760.03,
p = 0.033) and the interaction with older age at infection (estimate
+0.0760.03, p = 0.036) remained significantly associated with
FPR.
Discussion
In this paper, we showed that in a prospective cohort with
careful estimation of the date of infection and absence of major
confounders the PNPLA3 I148M sequence variant influences
fibrosis progression in CHC.
Homozygosity for the I148M variant, which in line with the
prevalence in the Italian population [29] was detected in about
one in ten subjects, was associated an average incremental
progression of fibrosis stage of as much as circa 0.8 units of Ishak
score per year. The link between 148M/M status and FPR was
independent of known moderators of fibrogenesis in CHC
[2,3,30], and remained robust even after extensive adjustment
for other potential confounders.
Our study is the first to show that the effect of PNPLA3 I148M
on fibrosis progression in CHC is modulated by the age at
infection. The negative impact of 148M/M on FPR in individuals
infected at older age was confirmed in sensitivity analyses with
lower age cut-offs, and was prominent in individuals infected in
adulthood. Previous studies suggested that PNPLA3 I148M
modulates liver damage progression in an age-dependent fashion.
However, despite older age at onset was associated with faster
progression of liver damage in alcoholic liver disease, the effect size
of 148M/M was larger in younger patients [19]. Similarly, the
reported effect size of the PNPLA3 I148M variant on liver
damage in nonalcoholic fatty liver disease was larger in pediatric
case series [14–16].
The reason underlying the opposite direction of modulation by
age of the effect of PNPLA3 I148M on fibrosis progression in
CHC is presently unknown. It could be speculated that the pattern
of activation of the immune system towards HCV is different
depending on the age at infection. According to this hypothesis,
HCV infection after the developmental age would lead to
immune-mediated hepatic damage, exerting a permissive role on
PNPLA3 I148M-related fibrogenesis [31]. Alternatively, older age
may synergize with PNPLA3 I148M in determining hepatic
steatosis, which would favor viral replication during the acute
infection [32], thus setting the stage for faster disease progression.
Indeed, evidence is accumulating that PNPLA3 I148M
synergizes with host features and environmental triggers in
determining liver damage associated with altered hepatic lipid
metabolism [33]. In line with these data, we found that the effect
of PNPLA3 148M/M on fibrogenesis was more evident in
subjects with grade 2–3 steatosis, and in those with other
conditions favoring hepatocellular lipid accumulation, such as
infection with genotype 3 and overweight.
Of note, we reported for the first time an effect of 148M/M on
fibrosis progression in genotype 3 patients, even if previous studies
did not detect an association between PNPLA3 and steatosis in
this subgroup [34,35]. However, since this finding was based on
FPR assessment in only two 148M/M patients infected with HCV
G3, it will require confirmation in future studies. Most impor-
tantly, the effect of 148M/M on fibrogenesis was independent of
the histological severity of steatosis. These data are in line with
results of cross-sectional studies in nonalcoholic fatty liver disease
[33], and suggest that PNPLA3 I148M may promote fibrogenesis
by directly altering hepatic stellate cells lipid metabolism and
trans-activation [36].
Therefore, given the independent association of the PNPLA3
I148M variant with fibrosis progression and hepatocellular
carcinoma risk [24], PNPLA3 I148M genotyping may help
refining treatment prioritization to novel therapeutic regimens
based on direct antiviral agents [37], and patients follow-up.
Limitations of this study include the assumption of the absence
of liver fibrosis at the time of infection, which is likely given the
absence of cofactors of liver damage, the young age at infection
and low risk profile. Furthermore, the model tested assumes the
consistency and linearity of FPR during time, and of fibrosis
progression across Ishak score stages, which are approximations of
a more complex reality [38]. Notwithstanding, the present results
are corroborated by the fact that our approach was able to validate
the association of FPR with the major risk factors for fibrosis
progression in CHC [3], and by independent findings linking
PNPLA3 148M/M with fibrogenesis in CHC [25,33].
Conclusions
In conclusion, homozygosity for the PNPLA3 I148M variant is
associated with FPR in CHC. There is a significant interaction
between age at infection and PNPLA3 genotype in determining
fibrosis progression, but the association between PNPLA3 and
Table 3. Effect of PNPLA3 148M/M on (log10) FPR in 247 CHC patients according to steatosis severity and the presence of risk
factors for steatosis/altered hepatic lipid metabolism (HCV-G3 and overweight).
PNPLA3 p value
148I/I or I/M 148M/M
Steatosis grade
0–1 21.0660.3 (172) 21.0760.3 (14) ns
2–3 20.9760.3 (42) 20.6760.2 (5) 0.024
HCV genotype
G1, G2, G4 21.0660.3 (194) 21.0060.3 (19) ns
G3 20.9260.3 (32) 20.7060.0 (2) 0.005
Overweight
BMI#25 Kg/m2 21.0160.3 (116) 21.1360.3 (8) ns
BMI.25 Kg/m2 21.0760.3 (110) 20.8760.2 (13) 0.05
(): number of subjects; BMI: body mass index; ns: not significant.
doi:10.1371/journal.pone.0106022.t003
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FPR is independent of the histological severity of steatosis. These
findings further establish the PNPLA3 I148M variant as a
moderator of CHC natural history, and have possible relevance
for treatment prioritization and follow-up of CHC patients.
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